VF
ATNM icon

Virtu Financial’s Actinium Pharmaceuticals ATNM Stock Holding History

Virtu Financial’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Buy
+12,324
New +$14.7K ﹤0.01% 1442
2024
Q4 		– Sell
-13,748
Closed -$26K – 1537
2024
Q3 		$26K Sell
13,748
-7,222
-34% -$28.5K ﹤0.01% 1098
2024
Q2 		$155K Sell
20,970
-61,059
-74% -$503K 0.01% 765
2024
Q1 		$642K Buy
82,029
+62,459
+319% +$402K 0.05% 340
2023
Q4 		$99K Buy
+19,570
New +$101K 0.01% 1032
2023
Q2 		– Sell
-21,650
Closed -$205K – 1504
2023
Q1 		$205K Sell
21,650
-5,204
-19% -$54.9K 0.02% 738
2022
Q4 		$286K Buy
26,854
+14,264
+113% +$145K 0.04% 513
2022
Q3 		$93K Sell
12,590
-23,199
-65% -$144K 0.01% 1100
2022
Q2 		$172K Buy
35,789
+21,699
+154% +$123K 0.01% 804
2022
Q1 		$72K Buy
14,090
+70
+0.5% +$369 0.01% 1047
2021
Q4 		$84K Buy
+14,020
New +$105K 0.01% 1198
2021
Q1 		– Sell
-27,524
Closed -$215K – 1585
2020
Q4 		$215K Buy
+27,524
New +$299K 0.02% 812
2020
Q3 		– Sell
-22,287
Closed -$235K – 1040
2020
Q2 		$235K Buy
+22,287
New +$169K 0.03% 650
2019
Q4 		$89K Buy
13,593
+10,151
+295% +$70K 0.01% 1103
2019
Q3 		$24K Buy
3,442
+1,035
+43% +$7.2K ﹤0.01% 1274
2019
Q2 		$18K Sell
2,407
-493
-17% -$4.95K ﹤0.01% 1354
2019
Q1 		$42K Buy
2,900
+96
+3% +$1.53K ﹤0.01% 1232
2018
Q4 		$33K Sell
2,804
-3,717
-57% -$63.4K ﹤0.01% 1317
2018
Q3 		$146K Buy
6,521
+3,311
+103% +$67.4K 0.01% 1138
2018
Q2 		$62K Buy
3,210
+2,698
+527% +$34.2K ﹤0.01% 1723
2018
Q1 		$6K Sell
512
-2,750
-84% -$46.7K ﹤0.01% 1864
2017
Q4 		$65K Buy
3,262
+1,870
+134% +$37.6K ﹤0.01% 2023
2017
Q3 		$24K Buy
+1,392
New +$30.5K ﹤0.01% 2316

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial's ATNM Position: Q1 2026 in Review

Virtu Financial opened a new position in Actinium Pharmaceuticals (ATNM) in Q1 2026: 12,324 shares worth $12K. The stake represents ﹤0.01% of the portfolio and ranks #1442 among its holdings. This is a return to the name: Virtu Financial previously reported a position in ATNM as recently as Q3 2024.

Virtu Financial first reported a position in ATNM in Q3 2017 and has held it in 23 quarters since. The position peaked at $642K in Q1 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Virtu Financial held 12,324 shares of Actinium Pharmaceuticals worth $12K as of Q1 2026.
  • Actinium Pharmaceuticals was a new Virtu Financial position in Q1 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1442 holding.
  • Virtu Financial first reported a position in Actinium Pharmaceuticals in Q3 2017 and has held it in 23 quarters since.
  • Virtu Financial's Actinium Pharmaceuticals position peaked at $642K in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.